High-density lipoprotein lifts the “dark web” cast by neutrophils

High-density lipoprotein lifts the “dark web” cast by neutrophils

Diego Lucero, Edward B. Neufeld, Alan T. Remaley

Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Correspondence to: Dr. Alan T. Remaley. National Heart, Lung and Blood Institute. Bldg. 10, Rm 2C-433, 10 Center Drive, Bethesda, MD 20892-1508, USA. Email: alan.remaley@nih.gov.

Provenance: This is an invited Editorial commissioned by Section Editor Kaiping Zhang (AME College, AME Group, China).

Comment on: Westerterp M, Fotakis P, Ouimet M, et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis and Atherogenesis. Circulation 2018;138:898-912.

Submitted Sep 06, 2018. Accepted for publication Sep 12, 2018.

doi: 10.21037/atm.2018.09.28

In a recent publication, in Circulation, Westerterp and co-workers (1) reveal novel mechanisms for how NLRP3 inflammasome activation enhances atherosclerosis and further show that high-density lipoprotein (HDL) counteracts this activation. They report that ATP Binding Cassette A1 and G1 (ABCA1/ABCG1) deficiency in myeloid cells increases plasma interleukin-18 (IL-18) levels in Ldlr-/- mice on a western type diet by a NLRP3 inflammasome-dependent process. The knock-out of Nlrp3 or Caspase1/11 obliterated the increase in IL-18, confirming a central role of the NLRP3 inflammasome in inflammation induced by myeloid ABCA1/G1 deficiency. This may turn out to be a key finding in unraveling the complicated relationship between HDL, inflammation and atherosclerosis.

The inverse association between HDL-cholesterol and cardiovascular disease has been long known (2,3); however, recent attempts to increase HDL cholesterol by novel drugs have failed in their goal to reduce cardiovascular events (4,5). This paradox could be related to the surprising complexity of the protein and lipid composition of HDL, which can alter HDL function. Recent studies have demonstrated that among the many purported HDL anti-atherogenic functions, cholesterol efflux is closely inversely associated to cardiovascular risk and in fact appears to better correlate with the anti-atherogenic property of HDL than HDL-cholesterol (6,7). HDL actively accepts free cholesterol from the membrane of peripheral cells through the specific transporters ABCA1 and ABCG1, as well as by a passive concentration gradient dependent process (8).

The infiltration of inflammatory cells in atherosclerotic lesions and increased levels of circulating cytokines in patients with cardiovascular disease have also revealed the importance of inflammation in the pathogenesis of atherosclerosis (9). Most notably, interleukin 1β (IL-1β), a pro-inflammatory cytokine, has been shown to induce the expression of adhesion molecules in endothelial cells, stimulate the proliferation of smooth muscle cells in lesions and notably, activates cells of innate immunity, especially macrophages (10). In the CANTOS trial, canakinumab, a neutralizing monoclonal antibody against IL-1β, was shown to reduce the occurrence of cardiovascular events in secondary prevention, independent of any changes in plasma lipids (11). IL-1β is first produced as pro-IL-1β and proteolytically activated by Caspase 1, which in turn is activated by the inflammasome, a large multi-component molecular complex found in the cytoplasm of cells involved in innate immunity (12). Another pro-inflammatory cytokine activated by Caspase 1 is IL-18, which is also associated with atherosclerosis (13).

The inflammasome initiates the innate inflammatory response by the recognition of “danger signals”. In particular, the NLRP3 inflammasome appears to be critical for atherogenesis; abrogation of NLRP3 function in bone marrow transplantation studies blocks atherosclerosis development in animal models (14). NLRP3 expression levels are also increased in the aorta of patients with coronary atherosclerosis (15). Neutrophils constitute the most abundant leukocytes in blood and are important effectors of innate immunity, particularly inflammasome activation, but their role in atherosclerosis has been difficult to establish (16). Even less understood is how HDL may modulate this process.

In their publication, Westerterp et al. found that, at early stages of atherosclerosis, myeloid deficiency in ABCA1/G1 caused neutrophilia, increased neutrophil infiltration in atherosclerotic plaques and a greater extent of neutrophil extracellular traps (NETs), which are extracellular nets made of DNA and granular proteins that can trap pathogens and are released by neutrophils when they are activated (1). Furthermore, they showed that the absence of inflammasome machinery, namely NLRP3 and Caspase1/11, blocked all these steps. Previously, transplantation of Abca1/Abcg1 deficient bone marrow into Ldlr-/- mice showed that neutrophilia and monocytosis increased atherosclerotic lesions (17). Thus, ABCA1/G1 deficiency in progenitor cells in bone marrow would cause systemic myeloid cellular cholesterol accumulation, inflammasome activation and neutrophil proliferation in bone marrow, ending with neutrophil recruitment in atherosclerotic plaque. Remarkably, neutrophil granule proteins can also attract monocytes to the atherosclerotic lesion site (16).

Although there are some conflicting studies on this point, phagocytosis of cholesterol crystals by macrophages appears to result in lysosomal damage, which then triggers NLRP3 inflammasome activation (14,18). In their publication, Westerterp et al. also observed that increased esterified and free cholesterol in splenic neutrophils was associated with inflammasome activation (1), which would provide a mechanism whereby early cholesterol deposition in atherosclerotic plaque could trigger inflammation.

In a previous study, we showed that incubation of THP-1 cells and human primary macrophages with HDL decreased the expression of inflammasome components, such as NLRP3 and IL-1β, and also reduced the activation of Caspase1 (19). Similarly, Westerterp and co-workers found that the injection of reconstituted HDL (rHDL) into myeloid ABCA1/G1 deficient Ldlr-/- mice reversed the increase in IL-18 (1), also suggesting that HDL can counteract inflammasome activation. In this model, the HDL effect could only be exerted by enhancing passive cholesterol efflux from cells, since myeloid cells lacked ABCA1/G1 transporters. This suggests that cholesterol enrichment in cell membranes, in the form of cholesterol crystals or not, can potentiate inflammasome activation.

As mentioned above, NLRP3 inflammasome induces Caspase1 activation, leading to the secretion of IL-1β and IL-18 (12). However, under some circumstances a non-canonical pathway can be involved, mediated by murine Caspase11, or the human counterparts Caspase4/5, activated by lipopolysaccharide (LPS) (20). Westerterp et al. found elevated Caspase11 activation in neutrophils and macrophages. Moreover, they performed LPS mortality experiments on myeloid ABCA1/G1 deficient Ldlr-/- mice, with and without concomitant knock-out of Nlrp3 or Caspase1/11. Interestingly, Caspase1/11 knock-out mice were resistant to LPS-induced death, regardless if they were myeloid ABCA1/G1 deficient or not; whereas myeloid ABCA1/G1 deficient animals, were the most susceptible to LPS-induced death, even when they lack NLRP3 expression in their myeloid cells (1). These data suggest greater inflammasome priming in myeloid ABCA1/G1 deficiency, and that inflammasome activation in ABCA1/G1 deficiency is upstream of NLRP3. In this scenario, cholesterol accumulation in myeloid cell membranes would favor inflammasome activation by the non-canonical pathway.

Tangier Disease is a rare autosomal recessive disease due to ABCA1 deficiency that leads to a marked reduction in HDL cholesterol and the accumulation of cholesterol in peripheral tissues, particularly macrophages. Westerterp and co-workers found increased levels of IL-1β and IL-18 in Tangier Disease patients in comparison to controls, suggesting NLRP3 inflammasome activation (1). Besides Tangier Disease, other more common conditions characterized by increased “C” reactive protein (CRP), a marker for low-grade inflammation, also have been shown to have reduced levels of ABCA1 in myeloid cells. Type 2 diabetic patients, for example, have decreased expression of Abca1 in blood leukocytes (21). Similar results have been observed in monocytes from obese/overweight patients (22) and in chronic kidney disease (CKD) patients (23). Furthermore, in type 2 diabetes and in CKD there is increased IL-18 and IL-1β in circulating monocytes (24,25), suggesting a possible pro-atherogenic role of the inflammasome in these common disorders.

In conclusion, this interesting study shows how the deficiency of ABCA1 and ABCG1 in myeloid cells induces cholesterol accumulation in cell membranes, which then favors NLRP3 inflammasome activation or Caspase11 mediated non-canonical inflammasome activation, even in the absence of cholesterol crystals. It also provides a novel mechanism for linking the cholesterol efflux function of HDL with inflammation. Finally, these results reveal that NLRP3 or the non-canonical pathway for inflammasome activation could be potential targets for the development of new drugs for the prevention of cardiovascular disease.


Funding: This research was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) (HL006095) at National Institutes of Health.


Conflicts of Interest: The authors have no conflicts of interest to declare.


  1. Westerterp M, Fotakis P, Ouimet M, et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis and Atherogenesis. Circulation 2018;138:898-912. [Crossref] [PubMed]
  2. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14. [Crossref] [PubMed]
  3. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92. [Crossref] [PubMed]
  4. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67. [Crossref] [PubMed]
  5. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012;53:1755-66. [Crossref] [PubMed]
  6. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35. [Crossref] [PubMed]
  7. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93. [Crossref] [PubMed]
  8. Phillips MC. Molecular mechanisms of cellular cholesterol efflux. J Biol Chem 2014;289:24020-9. [Crossref] [PubMed]
  9. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22. [Crossref] [PubMed]
  10. Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol 2017;70:2278-89. [Crossref] [PubMed]
  11. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017;377:1119-31. [Crossref] [PubMed]
  12. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015;21:677-87. [Crossref] [PubMed]
  13. Jefferis BJ, Papacosta O, Owen CG, et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis 2011;217:227-33. [Crossref] [PubMed]
  14. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61. [Crossref] [PubMed]
  15. Zheng F, Xing S, Gong Z, et al. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ 2013;22:746-50. [Crossref] [PubMed]
  16. Pende A, Artom N, Bertolotto M, et al. Role of neutrophils in atherogenesis: an update. Eur J Clin Invest 2016;46:252-63. [Crossref] [PubMed]
  17. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010;328:1689-93. [Crossref] [PubMed]
  18. Samstad EO, Niyonzima N, Nymo S, et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol 2014;192:2837-45. [Crossref] [PubMed]
  19. Thacker SG, Zarzour A, Chen Y, et al. High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology 2016;149:306-19. [Crossref] [PubMed]
  20. Yi YS. Caspase-11 non-canonical inflammasome: a critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses. Immunology 2017;152:207-17. [Crossref] [PubMed]
  21. Patel DC, Albrecht C, Pavitt D, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One 2011;6:e22142. [Crossref] [PubMed]
  22. Xu M, Zhou H, Wang J, et al. The expression of ATP-binding cassette transporter A1 in Chinese overweight and obese patients. Int J Obes (Lond) 2009;33:851-6. [Crossref] [PubMed]
  23. Ganda A, Yvan-Charvet L, Zhang Y, et al. Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD. J Mol Cell Cardiol 2017;112:114-22. [Crossref] [PubMed]
  24. Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013;62:194-204. [Crossref] [PubMed]
  25. Granata S, Masola V, Zoratti E, et al. NLRP3 inflammasome activation in dialyzed chronic kidney disease patients. PLoS One 2015;10:e0122272. [Crossref] [PubMed]
Cite this article as: Lucero D, Neufeld EB, Remaley AT. High-density lipoprotein lifts the “dark web” cast by neutrophils. Ann Transl Med 2018;6(Suppl 1):S24. doi: 10.21037/atm.2018.09.28